Can Novo’s Oral Semaglutide Shake Up Indian Diabetes Segment?
Executive Summary
Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?
You may also be interested in...
APAC Regulatory Roundup: Infectious Disease A Common Theme As COVID Lingers
A roundup of key regulatory and policy developments in the Asia-Pacific in the first half of the year reveals broad developments across the region's diverse markets, although there seemed to be a common thread - a renewed focus on infectious diseases amid the lingering impact of the pandemic and the emergence of new threats.
Novo Nordisk Enjoys Obesity Sales Boost Despite Wegovy Supply Issues
Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.
High Stakes: Boehringer Faces Pre-Expiry India Jardiance Challenge
Indian firms debut empagliflozin copies ahead of expected patent expiry for diabetes blockbuster Jardiance in the country. Spotlight now on how swiftly Boehringer Ingelheim can fend off the entrants and whether the local challenge goes well beyond “inspiration” from the goings-on in the case of another SGLT2 inhibitor dapagliflozin.